- Home
- PSEC vs AUPH Comparison
PSEC vs AUPH Comparison
Compare PSEC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PSEC | AUPH |
|---|---|---|
| Founded | 2004 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.6B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | PSEC | AUPH |
|---|---|---|
| Price | $2.69 | $14.75 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $2.50 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 4.1M | 872.5K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 19.78% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 2.07 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | N/A | $17.35 |
| Revenue Next Year | N/A | $15.66 |
| P/E Ratio | ★ N/A | $6.92 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $2.45 | $6.83 |
| 52 Week High | $4.36 | $16.54 |
Technical Indicators
Market Signals| Indicator | PSEC | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 40.74 | 53.64 |
| Support Level | $2.55 | $14.56 |
| Resistance Level | $2.71 | $15.23 |
| Average True Range (ATR) | 0.09 | 0.56 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 8.75 | 73.55 |
Price Performance
Historical ComparisonAbout PSEC Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests mainly in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.